Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KRAS | P01116 | 17/20 | 0.78 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.38 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.38 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21099262 | 0.92 | KRAS (0.66) | KRASSMARCA2SMARCA4PBRM1HDAC6 | |
| SCHEMBL21099390 | 0.89 | KRAS (0.61) | KRASSMARCA2SMARCA4PBRM1HDAC6 | |
| SCHEMBL21099388 | 0.88 | KRAS (0.60) | KRASSMARCA2SMARCA4PBRM1HDAC6 | |
| SCHEMBL21050693 | 0.88 | KRAS (1.00) | KRAS | |
| SCHEMBL21050678 | 0.88 | KRAS (1.00) | KRAS | |
| SCHEMBL21136668 | 0.88 | KRAS (1.00) | KRAS | |
| SCHEMBL21099333 | 0.87 | KRAS (0.78) | KRASSMARCA2SMARCA4PBRM1HDAC6 | |
| SCHEMBL21099392 | 0.85 | KRAS (0.65) | KRASSMARCA2SMARCA4PBRM1HDAC6 | |
| SCHEMBL21099629 | 0.84 | KRAS (0.71) | KRASSMARCA2SMARCA4PBRM1HDAC6 | |
| SCHEMBL21050914 | 0.82 | KRAS (0.52) | KRASSMARCA2SMARCA4PBRM1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10597405-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2020-03-24 | — | — | US | disclosed |
| WO-2019110751-A1 | TETRACYCLIC COMPOUNDS AS INHIBITORS OF G12C MUTANT RAS PROTEIN, FOR USE AS ANTI-CANCER AGENTS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | WO | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
| US-20190177338-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177338-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, MCL1 | KRAS 272/4885SMARCA2 2068/4885SMARCA4 1478/4885 |
| US-10597405-B2 | Chemical compounds | MKI67, CCNI, MCL1 | KRAS 272/4885SMARCA2 2068/4885SMARCA4 1478/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.